

UNIVERSITY^{OF} BIRMINGHAM

Subscriber access provided by University of Birmingham

Article

General Synthesis of Tri-carbo-substituted N2-Aryl-1,2,3-Triazoles via Cu-catalyzed Annulation of Azirines with Aryldiazonium Salts

Fangfang Feng, Jun-Kuan Li, Xuan-Yu Liu, Fa-Guang Zhang, Chi Wai Cheung, and Jun-An Ma J. Org. Chem., Just Accepted Manuscript • DOI: 10.1021/acs.joc.0c01433 • Publication Date (Web): 20 Jul 2020 Downloaded from pubs.acs.org on July 23, 2020

Just Accepted

"Just Accepted" manuscripts have been peer-reviewed and accepted for publication. They are posted online prior to technical editing, formatting for publication and author proofing. The American Chemical Society provides "Just Accepted" as a service to the research community to expedite the dissemination of scientific material as soon as possible after acceptance. "Just Accepted" manuscripts appear in full in PDF format accompanied by an HTML abstract. "Just Accepted" manuscripts have been fully peer reviewed, but should not be considered the official version of record. They are citable by the Digital Object Identifier (DOI®). "Just Accepted" is an optional service offered to authors. Therefore, the "Just Accepted" Web site may not include all articles that will be published in the journal. After a manuscript is technically edited and formatted, it will be removed from the "Just Accepted" Web site and published as an ASAP article. Note that technical editing may introduce minor changes to the manuscript text and/or graphics which could affect content, and all legal disclaimers and ethical guidelines that apply to the journal pertain. ACS cannot be held responsible for errors or consequences arising from the use of information contained in these "Just Accepted" manuscripts.

is published by the American Chemical Society. 1155 Sixteenth Street N.W., Washington, DC 20036

Published by American Chemical Society. Copyright © American Chemical Society. However, no copyright claim is made to original U.S. Government works, or works produced by employees of any Commonwealth realm Crown government in the course of their duties.

7 8

9 10

11

12 13

14 15

16

17

18 19

27

28 29

30 31

32

33

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58

59

60

General Synthesis of Tri-carbo-substituted №-Aryl-1,2,3-Triazoles via Cu-catalyzed Annulation of Azirines with Aryldiazonium Salts

Fang-Fang Feng,[†] Jun-Kuan Li,[†] Xuan-Yu Liu,[†] Fa-Guang Zhang,^{†, ‡} Chi Wai Cheung,^{*, †, ‡} and Jun-An Ma^{*, †, ‡}

- [†] Department of Chemistry, Tianjin Key Laboratory of Molecular Optoelectronic Sciences, Frontiers Science Center for Synthetic Biology (Ministry of Education), and Tianjin Collaborative Innovation Centre of Chemical Science & Engineering, Tianjin University, Tianjin 300072, P. R. of China
- ^{*} Joint School of National University of Singapore and Tianjin University, International Campus of Tianjin University, Binhai New City, Fuzhou 350207, P. R. of China

Supporting Information Placeholder



ABSTRACT: The general synthesis of fully substituted N^2 -aryl-1,2,3-triazoles are hitherto challenging compared with the N^1 -aryl counterparts. Herein we describe a Cu-catalyzed annulation reaction of azirines and aryldiazonium salts. This regiospecific method allows access to a broad spectrum of tri-carbo N^2 -aryl-1,2,3-triazoles substituted with diverse aryl and alkyl moieties. Its utility is highlighted by the synthesis of several triazole precursors applicable in drug discovery, as well as novel chiral binaphthyl ligands bearing triazole moieties.

Introduction

1,2,3-Triazoles are prevalent functional compounds in medicinal and materials chemistry.^{1,2} Among them, N²-aryl-1,2,3-triazoles are important structural scaffolds found in numerous biologically active molecules in drug discovery, as exemplified in the orexin receptor antagonists, Suvorexant,³ Nemorexant,⁴ and Seltorexant,⁵ for treating insomnia. Transition metal-catalyzed N-arylations have long been employed as the conventional methods to access the target N^2 -aryl-1,2,3-triazoles,⁶ but the concomitant formations of N^1 -aryl regioisomeric side products are generally inevitable. Alternatively, annulation reactions using various synthetic synthons are the reliable strategies to deliver N²-aryl-1,2,3 triazoles in regiospecific manners.^{7,8} In this context, annulation reactions of nitrogen-based synthons with aryldiazonium salts have emerged as promising approaches to synthesize N²-aryl-1,2,3-triazoles⁸ thanks to the convenient preparations and broad scope of aryldiazonium salts.⁹ Noteworthily, fully substituted N^2 aryl-1,2,3-triazoles are especially valuable heterocycles due to the multiple versatilities and functionalities governed by the possible existence of three distinct substituents attached to the triazole rings. To this end, streamlined and modular strategies based on the judicious use of suitable synthons for Cu-mediated or -catalyzed annulation with aryldiazonium salts were recently described by Tang,^{8a} Yu,^{8d} and our group^{8e} to access a plethora of tri-substituted N^2 -aryl-1,2,3-triazoles bearing aryl, thio, keto, and ester moieties. Importantly, Jiang and co-workers described a Cucatalyzed annulation reaction of oxime acetates with electron-rich *p*-methoxyphenyl-diazonium salt in order to obtain tri-carbo N²-aryl-1,2,3-triazoles in high yields^{8b} (Scheme 1a). Recently, azirines, a class of reactive and readily accessible substrates capable of bearing di-aryl- or aryl-/alkyl-substituents, have been employed as atomeconomic synthons to access a vast number of nitrogen heterocyclic compounds¹⁰ Based on our continuous endeavors in utilizing aryldiazonium salts for heterocycle synthesis,^{8e,11} we envisioned that the annulation of azirines with aryldiazonium salts would also be feasible to access structurally diverse tri-carbo *N*²-aryl-1,2,3-triazoles (Scheme 1b). This alternative strategy complements the precedented protocols, further extending the scope of tricarbo N^2 -aryl-1,2,3-triazole compounds. Herein we describe our discoveries based on this subject.

Scheme 1. Cu-catalyzed annulation of aryldiazonium salts for construction of tri-carbo *N*²-aryl-1,2,3-triazoles.

ACS Paragon Plus Environment

(a) Jiang's work: Cu-catalyzed cycloaddition of Ac-oximes with ArN_2^+



Results and Discussions

Initially, 2,3-diphenyl-2*H*-azirine (1a)and 4tolyldiazonium tetrafluoroborate (2a) were used as model substrates for study (Table 1). To our delight, 1a reacted with 3 equivalents of 2a in the presence of CuCl catalyst (20 mol %) and Li_2CO_3 (1 equiv) as base additive in toluene solvent at 40 °C in 12 h, furnishing the desired product, 4,5diphenyl-2-(p-tolyl)-2H-1,2,3-triazole (3a), in 48% yield (Entry 1). Cu catalyst was crucial in this transformation, as no product was formed when CuCl was omitted (Entry 2). Base was also essential in the reaction, as the yield dropped in the absence of base (Entry 3). CuBr was found to be the superior Cu catalyst, slightly improving the yield to 50% (Entries 4-8). In the presence of organic base 1,4diazabicyclo[2.2. 2]octane (DABCO), the yield of **3a** was enhanced to 75%, presumably owing to its moderate basicity and better solubility (Entry 9-13). Additionally, the yield of 3a could be promoted to 93% using acetonitrile (MeCN) as the polar aprotic solvent (Entries 14-17). The reaction remained efficient at room temperature and in the presence of 2 equivalents of 2a without loss of vield (Entry 18). Subsequent reducing the loadings of 2a, base, and catalyst slightly diminished the yields accordingly (Entry 19-21).

Table 1. Optimizations of reaction conditions.^a

Ph P 1a (1 equiv)	⊕ h <i>p</i> -TolyI—N∃ h 2a (3 equ	⊖ (■N BF4 —	Cu catalyst (20 mol % additive (1 equiv) solvent, 40 °C, 12 h	$ \xrightarrow{p-Tolyl} N \xrightarrow{N} N \xrightarrow{N} N \xrightarrow{Ph} Ph \xrightarrow{3a} $
Entry	Cu catalyst	base	Solvent	Yield (%) ^b
1	CuCl	Li ₂ CO ₃	toluene	48
2	none	Li ₂ CO ₃	toluene	0
3	CuCl	none	toluene	40
4	CuBr	Li ₂ CO ₃	toluene	50
5	CuI	Li ₂ CO ₃	toluene	8
6	CuTc	Li ₂ CO ₃	toluene	48
7	CuOAc	Li ₂ CO ₃	toluene	5
8	CuCl ₂	Li ₂ CO ₃	toluene	45
9	CuBr	Na ₂ CO	3 toluene	20

10	CuBr	K ₂ CO ₃	toluene	18
11	CuBr	Et_3N	toluene	<5
12	CuBr	DBU	toluene	25
13	CuBr	DABCO	toluene	75
14	CuBr	DABCO	Et_2O	47
15	CuBr	DABCO	EtOH	74
16	CuBr	DABCO	CH_2Cl_2	89
17	CuBr	DABCO	MeCN	93
18 ^{c,d}	CuBr	DABCO	MeCN	93
19 ^{c,e}	CuBr	DABCO	MeCN	80
20 ^{c,f}	CuBr	DABCO	MeCN	85
21 ^{c,g}	CuBr	DABCO	MeCN	86

^{*a*} Reaction conditions: **1a** (0.2 mmol), **2a** (0.6 mmol), Cu catalyst (20 mol %), additive, solvent (2 mL), argon atmosphere, 40 °C, 16 h. ^{*b*} Isolated yield. ^{*c*} Reaction was conducted at room temperature for 16 h. ^{*d*} **2a** (2 equiv.). ^{*e*} **2a** (1.5 equiv.). ^{*f*} DABCO (0.5 equiv.). ^{*g*} CuBr (10 mol %).

The optimized reaction protocol (Table 1, entry 17) proved to be versatile (Scheme 2). Electron-rich (**3a-3h**), electron-neutral (3i), and electron-deficient aryldiazonium salts (**3j-3r**) all reacted to give the corresponding *N*²-aryl 1,2,3-triazoles in generally good to excellent yields (65%-96%). Likewise, para-, meta-, and ortho-substituted aryldiazonium salts underwent annulation to afford the triazoles in similar yields (3f-3h, 3o-3q). Additionally, dihalo-substituted diazonium salts (3r), as well as sterically bulky 2-naphthyl- (3s) and 2-phenylbenzene-diazonium salts (3t), were suitable reaction substrates to deliver the triazoles in good to high yields. Furthermore, thienyl (3u) and quinoline moieties (3v) could also be incorporated to the triazole products. A wide range of functional groups were compatible in this protocol, including amino (3e), trifluoromethyl (3j), keto (3k), iodo (3l), bromo (3m), fluoro (3n), chloro (3o-3q), and ester groups (3u). This protocol was amenable to the large-scale synthesis of triazole **3f** in equally high yield. However, monosubstituted 3-phenylazirine reacted to give a trace of triazole, suggesting that the additional substituent is necessary to assist the stabilization of reaction intermediates.

The protocol also allowed for the use of a variety of 2,3di-sibstituted azirines, affording the unsymmetrical N^2 aryl-1,2,3-triazoles in good to excellent yields (Scheme 3). Electron-rich (4a, 4f) and electron-withdrawing aryl groups (4b, 4c, 4g, 4i), as well as heteroaryl groups (4d), could all be incorporated on both 2- and 3-positions of the azirine rings for triazole synthesis. Moreover, triazoles bearing methyl (4h, 4m), cyclopropyl (4i), n-pentyl (4j), 2phenylethyl (4k), and 1-phenylethyl groups (4l) in either 3or 4- positions were generated smoothly. Notably, the substituents at the 2- or 3-positions of azirine substrates were interchangeable, giving the identical triazole products in similar yields (4a and 4f; 4c and 4g; 4h and 4m). Given the broad scope and ready accessibility of aziridines as well as the scalability of the protocol, the method could offer an expedient and convenient synthesis of N^2 -aryl triazole for various industrial settings. Unfortunately, the monoalkyl-

or dialkyl substituted azirines were either unstable or inaccessible for further study.

Scheme 2. Substrate scope of aryldiazonium salts.^a



^{*a*} Reaction conditions: **1a** (0.3 mmol), **2a** (0.6 mmol), CuBr (0.06 mmol), DABCO (0.3 mmol), MeCN (3 mL), argon atmosphere, rt, 16 h. Isolated yields were presented. ^{*b*} 1.16 g of **1a** was used.

Scheme 3. Substrate scope of azirines.^a



^{*a*} Reaction conditions: **1** (0.3 mmol), **2a** (0.6 mmol), CuBr (0.06 mmol), DABCO (0.3 mmol), MeCN (3 mL), argon atmosphere, rt, 16 h. ^{*b*} Identical products were formed using two different azirines. Isolated yields were presented. ^{*c*} Reaction was conducted at 40 °C.

The derivatization of the tri-carbo *N*²-aryl-1,2,3-triazole products were viable. Triazole 3f could react with ceric ammonium nitrate $(CAN)^{12}$ to give the N²-H free, 3,4diphenyl 1,2,3-triazole 5 (Scheme 4a). 5 could further various *N*-alkyations¹³ to affords the undergo corresponding N^2 - and N^1 -alkylated triazole congeners 6-8 (Scheme 4b). In addition, regiospecific N²-arylation of **5** was accessible via nucleophilic aromatic substitution with various fluoroarenes to afford **9a-9f**,¹⁴ allowing access to 1,2,3-triazole compounds with electron-deficient aryl groups and pyridyl groups at N^2 -positions (Scheme 4c). Indeed, triazoles 6-9 were difficult to directly produce using the current protocol. Overall, this N^2 -aryl triazole synthesis and *N*-dearylation strategy for elaborations would provide alternative routes to access a broad range of structurally and electronically diverse N^2 -substituted and NH-free triazoles.15

Scheme 4. Derivatizations of the triazole products.



Under this protocol, several methyl 2-(4',5'-diaryl-2'triazolyl)arenoate compounds **10a-10c** were readily synthesized using the corresponding azirines and aryldiazonium salts (Scheme 5a). These compounds could serve as precursors¹⁶ towards the modular synthesis of the analogues of orexin receptor antagonists.³⁻⁵ Moreover, (*S*)-[1,1'-binaphthalene]-2,2'-diamine was readily converted to the corresponding bis(diazonium) salt, which reacted with azirine **2a'** under the standard conditions to afford both mono- and bis-triazolyl substituted binaphthalenes, **11a** and **11b** (Scheme 5b). These novel class of chiral triazolylbinaphthalenes would be potentially applicable in asymmetric transition metal-catalyzed transformations or photocatalysis.¹⁷

Scheme 5. Synthetic utility of the reaction protocol.

(a) Synthesis of triazole scaffolds as drug precursors



To probe the mechanism of the Cu-catalyzed annulation reaction, 2,2,6,6-tetramethylpiperidin-1-yl)oxyl (TEMPO) was added as radical scavenger (Scheme 6a). The reaction became sluggish in the presence of 2 equivalents of TEMPO to form a trace of product **3a**. The adduct between TEMPO and azirine was also detected by HRMS analysis,^{10d} indicating that radical pathways are likely involved in the reaction process. In the proposed reaction mechanism (Scheme 6b), CuBr catalyst initially cleaves the C-N single bond of azirine to form radical intermediate **A**,^{10d} which further couples with aryldiazonium ion to form radical cation species **B**. Deprotonation of species **B** by DABCO furnishes radial species **C**, which then cyclizes to form the triazole product and regenerates CuBr for subsequent catalytic cycles.

Scheme 6. Probing of the reaction mechanism.

2

3

4

5

6

7

8

9

10 11 12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34 35

36 37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57 58 59

60





In conclusion, we have developed an annulation reaction of azirines with aryldiazonium salts. A diverse collection of tri-carbo N^2 -aryl-1,2,3-triazoles substituted with both aryl and alkyl moieties can be accessed in association with good functional group tolerance. The triazole compounds are readily diversified to other derivatives. The protocol also allows expedient access to several potential precursors of druglike molecules as well as novel chiral binaphthyl ligands. Preliminary study suggests that a radical mechanism likely takes place. Further expansion of the substrate scope and the catalytic applications of chiral ligand **11a** and **11b** are underway in our laboratory.

Experimental Section

General information

¹H, ¹³C and ¹⁹F NMR spectra were recorded on Bruker AV 400 MHz instrument at 400 MHz (¹H NMR), 100 MHz (¹³C NMR), and 376 MHz (¹⁹F NMR). Chemical shifts were reported in ppm down field from internal Me₄Si and external CHCl₃, respectively. Multiplicity was indicated as follows: s (singlet), d (doublet), t (triplet), q (quartet), m (multiplet), dd (doublet of doublet), and br (broad signal). Coupling constants were reported in Hertz (Hz). High resolution mass spectrometry (HRMS) spectra were obtained on a Bruker miorOTOF-QII instrument. Melting points were measured on a SGW X-4A digital melting point apparatus and are uncorrected. Optical rotations were determined using an Autopol IV automatic polarimeter. HPLC analyses were carried out on a HewlettPackard Model HP 1200 instrument. X-ray structural analysis was conducted on a Bruker APEX-II CCD instrument.

Tetrahydrofuran (THF), diethyl ether (Et₂O), and toluene were distilled from sodium/benzophenone prior to use; CH_2Cl_2 and CCl_4 was distilled from CaH_2 ; CH_3CN was distilled from P_2O_5 . All purchased reagents were used without further purification. Thin-layer chromatography (TLC) was performed on precoated GF254 silica gel plates (Qingdao Marine Chemical Inc.) and compounds were visualized with a UV light at 254 nm. Flash chromatography separations were carried out using silica gel (200–300 mesh, Qingdao Marine Chemical Inc.). Aryldiazonium salts 2^{11a} were prepared according to the reported procedures.

General procedure for synthesis of 2*H*-azirine (1).

(i) Method A (for synthesis of 1a, 1a' -1g' and 1i')¹⁸

0 ∥ ⊓2	1) NH ₂ OH · HCI NaOAc	HO N	2) MsCl, Et ₃ N DBU	
R^{1}	MeOH / H ₂ O, rt		THF, 0 °C	for 1a, 1a' -10' and 1i'

Step 1: A solvent mixture of MeOH/H₂O (20:1) was added to a mixture of ketone (10 mmol, 1 equiv), NH₂OH·HCl (1.5 equiv) and sodium acetate (1.5 equiv) in a round bottom flask. The resulting solution was stirred at room temperature and the reaction was monitored by TLC. After the reaction was completed, the solvent was removed in *vacuo* and CH₂Cl₂ (30 mL) was then added. The mixture was washed with saturated NaHCO₃ solution followed by brine. The organic fraction was dried over anhydrous Na₂SO₄ and concentrated in vacuo to give the oxime as the residue, which was used directly for the next step. Step 2: To a solution of the crude oxime (1 equiv, from step 1) in dry THF (30 mL) was added triethylamine (1.5 equiv) and methanesulfonyl chloride (1.5 equiv) sequentially at room temperature or at 0 °C. The solution became cloudy after the addition of methanesulfonyl chloride. The resulting mixture was stirred for 30 min, and DBU (1.5 equiv) was then added over 1 min. After stirring for additional 30 min, the reaction mixture was passed through a pad of silica gel and washed with Et_20 (30 mL x 3). The filtrate was concentrated in vacuo and the residue was purified by column chromatography using peteroleum ether and ethyl acetate (20:1) as eluent to afford the 2H-azirine 1a, 1a'-1g' and 1i'.

(ii) Method B (for synthesis of 1j' -1m')¹⁹

Ph
$$R^3 \xrightarrow{1) \text{ NaN_3, ICl}} Ph \xrightarrow{N_3} R^3 \xrightarrow{3) \text{ toluene}} Ph \xrightarrow{N_3} R^3 \xrightarrow{3) \text{ toluene}} R^3 R^3 \xrightarrow{100 \text{ °C}, 4 \text{ h}} R^3 R^3 \text{ Tj'-m'}$$

Step 1: To a suspension of NaN₃ (452 mg, 7.0 mmol, 2.5 equiv) in acetonitrile (2.2 mL) was added dropwise a solution of iodine monochloride (680 mg, 4.2 mmol, 1.5 equiv) in CH_2Cl_2 (3.6 mL) at -20°C, and the mixture was stirred at the same temperature. After 30 min, a solution of the corresponding alkene (2.8 mmol, 1.0 equiv) in CH_2Cl_2 (3.6 mL) was added slowly, and the mixture was stirred for additional 1 h. After the reaction, the reaction was quenched with saturated aqueous $Na_2S_2O_3$ (5 mL), and the reaction mixture were extracted with Et_2O (10 mL x 3). The combined organic fraction was washed with brine and dried over anhydrous Na₂SO₄. After evaporation of solvent, the resulting crude material was used immediately for the next step without any further purification. Step 2: To a solution of the crude material (from step 1) in Et₂O (8 mL) was added t-BuOK (374 mg, 3.3 mmol, 1.2 equiv) at 0°C, and the mixture was stirred for 1 h at the same temperature. After the reaction, the reaction mixture was quenched with H_2O (10 mL), and the organic materials were extracted with Et₂O (20 mL x 3). The combined organic fraction was washed with brine, dried over anydrous Na₂SO₄, and then dried *in vacuo*. The residue was purified by flash column chromatography using peteroleum ether and ethyl acetate (10:1) as eluent to give the corresponding vinyl azide. **Step 3:** A solution of the vinyl azide (from step 2) in toluene (15 mL) was heated at 100 °C for 4 h. After evaporation of solvent, the crude mixture was purified by flash column chromatography using peteroleum ether and ethyl acetate (20:1) as eluent to give the 2H-azirines **1j'-1m'**.

(iii) Method C (for synthesis of 1h')¹⁹

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

Ph Me	1) NaN ₃ , Nal CAN, MeOH	Ph Me 3) toluene	N
	2) <i>t</i> -BuOK, Et ₂ O	N ₃ 100 °C, 1.5 h	Me Ph

Step 1: To a mixture of alkene (6.0 mmol, 1.0 equiv), NaN₃ (390 mg, 6.0 mmol, 1.0 equiv), and NaI (900 mg, 6.0 mmol, 1.0 equiv) in methanol (9.0 mL) at 0 °C was added dropwise a solution of ceric ammonium nitrate (590 mg, 12.6 mmol, 2.1 equiv) in methanol (36 mL). Upon completion of the reaction as indicated by TLC, saturated aqueous NaHSO₃ (20 mL) was added, and the resulting mixture was extracted with CH₂Cl₂ (10 mL x 3) The combined organic fraction was washed with distilled water (24 mL) and saturated brine (24 mL), dried over anhydrous Na₂SO₄, and dried in vacuo. The resulting crude material was used immediately for the next step without any further purification. Step 2: To a solution of the crude material (from step 1) in dry Et₂O (20 mL) in an ice bath was added t-BuOK (1.34 g, 12.0 mmol, 2.0 equiv). The reaction mixture was stirred for 4 h at 0 °C and then washed with water (50 mL x 2). The combined organic fraction was dried over anhydrous Na₂SO₄, and the solvent was removed in vacuo. The residue was purified by column chromatography using peteroleum ether and ethyl acetate as eluent (10:1) to give the crresponding vinyl azide. Step 3: A solution of the vinyl azide (from step 2) in toluene (15 mL) was heated at 100°C for 1.5 h. After evaporation of solvent, the crude mixture was purified by flash column chromatography using peteroleum ether and ethyl acetate (20:1) as eluent to give the 2H-azirines 1h'.

General procedure A: Annulation Reaction of 2*H*-Azirines 1 and aryldiazonium salt 2. An oven-dried 10 mL Schlenk tube equipped with a stirring bar and capped with a rubber septum was charged with 2*H*-azirine (1, 1 equiv, 0.3 mmol), arene-diazonium salt (2, 2 equiv, 0.6 mmol), CuBr (20 mol%, 0.06 mmol), and DABCO (1 equiv, 0.3 mmol). The tube was evacuated under *vacuo* and then backfilled with argon (for three times). CH₃CN (3.0 mL) was transferred into the tube via a syringe. The resulting mixture was stirred under an argon atmosphere at room temperature for 16 h. The reaction mixture was concentrated *in vacuo*, and the residue was purified by flash chromatography on silica gel (eluting with petroleum ether / ethyl acetate) to give the desired N^2 -aryl-1,2,3-triazole products 3 and 4.

4,5-diphenyl-2-(p-tolyl)-2H-1,2,3-triazole (3a). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 86.8 mg (0.28 mmol), 93% yield, m.p. 105-107 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, J = 8.5 Hz, 2H), 7.65 (dd, J = 6.5, 3.1 Hz, 4H), 7.40 (dd, J = 4.9, 1.7 Hz, 6H), 7.30 (d, J = 8.3 Hz, 2H), 2.42 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 145.8, 137.8, 137.4, 131.1, 129.9, 128.7, 128.7, 128.6, 118.9, 21.2. HRMS (ESI) m/z calcd. for C₂₁H₁₈N₃⁺ 312.1501, found 312.1500 [M+H]⁺.

2-(3,5-dimethylphenyl)-4,5-diphenyl-2H-1,2,3-triazole (3b). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 78.1 mg (0.24 mmol), 80% yield, m.p. 108-110 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.82 (s, 2H), 7.66 (m, 4H), 7.45 – 7.33 (m, 6H), 7.00 (s, 1H), 2.42 (s, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 145.9, 139.8, 139.3, 131.0, 129.3, 128.7, 128.7, 128.6, 116.7, 21.5. HRMS (ESI) m/z calcd. for $C_{22}H_{20}N_3^+$ 326.1657, found 326.1658 [M+H]⁺.

2-(4-isopropylphenyl)-4,5-diphenyl-2H-1,2,3-

triazole (3c). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 93.8 mg (0.27 mmol), 90% yield, m.p. $108-110 \circ C. {}^{1}$ **H NMR** (400 MHz, CDCl₃) δ 8.19 - 8.04 (m, 2H), 7.68 (s, 4H), 7.50 - 7.29 (m, 8H), 3.08 - 2.87 (m, 1H), 1.32 (d, *J* = 6.6 Hz, 6H). 13 C{1H} **NMR** (100 MHz, CDCl₃) δ 148.4, 145.8, 137.9, 131.1, 128.7, 128.7, 128.6, 127.3, 119.0, 33.9, 24.1. **HRMS** (ESI) m/z calcd. for C₂₃H₂₂N₃⁺ 340.1814, found 340.1808 [M+H]⁺.

2-(4-(tert-butyl)phenyl)-4,5-diphenyl-2H-1,2,3-

triazole (3d). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 68.9 mg (0.20 mmol), 65% yield, m.p. 70–72 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.08 (d, *J* = 8.8 Hz, 2H), 7.65 (dd, *J* = 6.5, 3.1 Hz, 4H), 7.51 (d, *J* = 8.8 Hz, 2H), 7.42 – 7.37 (m, 5H), 7.36 – 7.29 (m, 1H), 1.38 (s, 9H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 150.8, 145.8, 137.6, 131.1, 128.7, 128.7, 128.6, 126.3, 118.7, 34.8, 31.5. **HRMS** (ESI) m/z calcd. for C₂₄H₂₄N₃⁺ 354.1970, found 354.1968 [M+H]⁺.

4-(4,5-diphenyl-2H-1,2,3-triazol-2-yl)-N,N-

dimethylaniline (3e). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.2), 71.5 mg (0.21 mmol), 70% yield, m.p. $145-147 \circ C. {}^{1}$ **H NMR** (400 MHz, CDCl₃) δ 8.03 (d, *J* = 9.1 Hz, 2H), 7.66 (dd, *J* = 7.4, 1.9 Hz, 4H), 7.46 – 7.29 (m, 6H), 6.80 (d, *J* = 9.1 Hz, 2H), 3.02 (s, 6H). 13 C{1H} **NMR** (100 MHz, CDCl₃) δ 150.0, 145.1, 131.4, 130.4, 128.7, 128.5, 128.5, 120.2, 112.4, 40.7, 40.5. HRMS (ESI) m/z calcd. for C₂₂H₂₁N₄⁺ 341.1766, found 341.1768 [M+H]⁺.

2-(4-methoxyphenyl)-4,5-diphenyl-2H-1,2,3-triazole

(3f). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.2$), 83.5 mg (0.26 mmol), 85% yield, m.p. 84–86 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, *J* = 9.1 Hz, 2H), 7.70 (dd, *J* = 6.5, 3.0 Hz, 4H), 7.50 – 7.35 (m, 6H), 7.05 (d, *J* = 9.1 Hz, 2H), 3.89 (s, 3H).

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

¹³C{1H} NMR (100 MHz, CDCl₃) δ 159.2, 145.7, 133.8, 131.2, 128.8, 128.7, 128.6, 120.4, 114.5, 55.8. HRMS (ESI) m/z calcd. for $C_{21}H_{18}N_3O^+$ 328.1450, found 328.1451 [M+H]⁺. For the reacton based on 6 mmol (1.16 g) of 2*H*-azirines, the product **3f** was obtained in 81% yield (1.59 g).

2-(3-methoxyphenyl)-4,5-diphenyl-2H-1,2,3-triazole (**3g**). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.2$), 92.3 mg (0.28 mmol), 94% yield, m.p. $100-102 \circ C$. ¹H NMR (400 MHz, CDCl₃) δ 7.87 – 7.74 (m, 2H), 7.75 – 7.62 (m, 4H), 7.42 (dd, J = 4.0, 2.8 Hz, 7H), 6.98 - 6.86 (m, 1H), 3.92 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 160.5, 146.1, 140.9, 130.9, 130.2, 128.8, 128.7, 128.6, 113.7, 111.2, 104.3, 55.7. HRMS (ESI) m/z calcd. for $C_{21}H_{18}N_3O^+$ 328.1450, found 328.1451 [M+H]⁺.

2-(2-methoxyphenyl)-4,5-diphenyl-2H-1,2,3-triazole

(3h). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.1), 84.5 mg (0.26 mmol), 86% yield, m.p. 92-94 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.65 (dd, J = 6.4, 2.1 Hz, 5H), 7.50 – 7.41 (m, 1H), 7.38 (dd, J = 5.0, 1.7 Hz, 5H), 7.15 – 7.03 (m, 2H), 3.90 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 153.9, 145.7, 131.0, 130.6, 129.9, 128.7, 128.6, 128.6, 127.4, 120.8, 113.0, 56.5. HRMS (ESI) m/z calcd. for C₂₁H₁₈N₃O⁺ 328.1450, found 328.1447 [M+H]⁺.

2,4,5-triphenyl-2H-1,2,3-triazole (3i). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 78.5 mg (0.26 mmol), 88% yield, m.p. 93-95 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.26 – 8.12 (m, 2H), 7.72 – 7.60 (m, 4H), 7.51 (t, *J* = 7.9 Hz, 2H), 7.47 – 7.37 (m, 6H), 7.36 (d, *J* = 7.5 Hz, 1H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 146.1, 139.9, 130.9, 129.4, 128.8, 128.7, 128.6, 127.5, 118.9. HRMS (ESI) m/z calcd. for C₂₀H₁₆N₃⁺ 298.1344, found 298.1349 [M+H]⁺.

4,5-diphenyl-2-(4-(trifluoromethyl)phenyl)-2H-1,2,3triazole (3j). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.2), 76.7 mg (0.21 mmol), 70% yield, m.p. 107–109 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.32 (d, *J* = 8.5 Hz, 2H), 7.77 (d, *J* = 8.6 Hz, 2H), 7.70 – 7.56 (m, 4H), 7.50 – 7.37 (m, 5H), 7.36 – 7.29 (m, 1H). ¹⁹**F NMR** (376 MHz, CDCl₃) δ -62.31. ¹³**C{1H} NMR** (100 MHz, CDCl₃) δ 147.3 (d, *J* = 261.7 Hz), 147.1, 142.1, 138.7, 130.3 (d, *J* = 43.6 Hz), 129.2, 128.8, 128.6, 128.4, 126.8 (q, *J* = 3.7 Hz). **HRMS** (ESI) m/z calcd. for C₂₁H₁₅N₃F₃⁺ 366.1218, found 366.1218 [M+H]⁺.

1-(4-(4,5-diphenyl-2H-1,2,3-triazol-2-

yl)phenyl)ethanone (3k). Following the geneal procedure A, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.2), 89.6 mg (0.26 mmol), 88% yield, m.p. 140–142 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.28 (d, *J* = 8.6 Hz, 2H), 8.10 (d, *J* = 8.6 Hz, 2H), 7.75 – 7.55 (m, 4H), 7.50 – 7.28 (m, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 197.0, 147.1, 142.8, 135.7, 130.5, 129.9, 129.1, 128.8, 128.6, 118.5, 26.8. HRMS (ESI) m/z calcd. for $C_{22}H_{18}N_30^+$ 340.1450, found 340.1458 [M+H]*.

2-(4-iodophenyl)-4,5-diphenyl-2H-1,2,3-triazole

(31). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.4$), 111.7 mg (0.26 mmol), 88% yield, m.p. 138-140 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.95 (d, J = 8.9 Hz, 2H), 7.82 (d, J = 8.9 Hz, 2H), 7.71 – 7.58 (m, 4H), 7.48 – 7.33 (m, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 146.4, 139.5, 138.4, 130.6, 128.9, 128.8, 128.6, 120.5, 92.1. HRMS (ESI) m/z calcd. for $C_{20}H_{15}N_3I^+$ 424.0311, found 424.0316 [M+H]⁺.

2-(4-bromophenyl)-4,5-diphenyl-2H-1,2,3-triazole (**3m**). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.4$), 99.3 mg (0.26 mmol), 88% yield, m.p. 117-119 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.08 (d, *J* = 8.9 Hz, 1H), 7.71 – 7.54 (m, 6H), 7.52 – 7.29 (m, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 146.5, 138.9, 132.5, 130.7, 128.9, 128.8, 128.6, 121.0, 120.3. HRMS (ESI) m/z calcd. for $C_{20}H_{15}N_3Br^+$ 376.0449, found 376.0443 [M+H]⁺.

2-(4-fluorophenyl)-4,5-diphenyl-2H-1,2,3-triazole (3n). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 80.4 mg (0.26 mmol), 85% yield, m.p. 106-108 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.27 – 8.05 (m, 2H), 7.73-7.56 (m, 4H), 7.49 – 7.36 (m, 6H), 7.19 (t, J = 8.6 Hz, 2H). ¹⁹F NMR (376 MHz, CDCl₃) δ -114.71. ¹³C{1H} NMR (100 MHz, CDCl₃) δ 161.9 (d, J = 246.9 Hz), 146.2, 136.2, 130.8, 128.9, 128.8, 128.6, 120.6 (d, J = 8.4 Hz), 116.2 (d, J = 23.1 Hz). HRMS (ESI) m/z calcd. for $C_{20}H_{15}N_3F^+$ 316.1250, found 316.1255 [M+H]⁺.

2-(4-chlorophenyl)-4,5-diphenyl-2H-1,2,3-triazole (**30**). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.4$), 85.6 mg (0.26 mmol), 86% yield, m.p. 83-85 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.24 – 8.01 (m, 2H), 7.77 – 7.56 (m, 4H), 7.47 (d, *J* = 9.0 Hz, 2H), 7.45 – 7.35 (m, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 146.4, 138.3, 133.0, 130.7, 129.5, 128.9, 128.7, 128.6, 120.0. HRMS (ESI) m/z calcd. for $C_{20}H_{15}N_3$ Cl⁺ 332.0955, found 332.0959 [M+H]⁺.

2-(3-chlorophenyl)-4,5-diphenyl-2H-1,2,3-triazole

(3p). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.4$), 95.6 mg (0.29 mmol), 96% yield, m.p. 76–78 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.24 (t, *J* = 1.9 Hz, 1H), 8.15 – 8.03 (m, 1H), 7.72 – 7.57 (m, 4H), 7.43 (dd, *J* = 9.6, 6.3 Hz, 8H), 7.37 – 7.28 (m, 1H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 146.6, 140.7, 135.3, 130.6, 130.5, 129.0, 128.8, 128.6, 127.4, 119.1, 116.9. HRMS (ESI) m/z calcd. for C₂₀H₁₅N₃Cl⁺ 332.0955, found 332.0948 [M+H]⁺.

2-(2-chlorophenyl)-4,5-diphenyl-2H-1,2,3-triazole

(**3q**). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography

60

Page 8 of 14

 $\begin{array}{l} (petroleum \ ether/ethyl \ acetate \ = \ 30:1, \ R_f \ = \ 0.4), \ 83.6 \ mg \\ (0.25 \ mmol), \ 84\% \ yield, \ m.p. \ 78-80 \ ^\circ C. \ ^1H \ NMR \ (400 \ MHz, \\ CDCl_3) \ \delta \ 7.82 \ - \ 7.72 \ (m, \ 1H), \ 7.72 \ - \ 7.63 \ (m, \ 4H), \ 7.64 \ - \ 7.54 \\ (m, \ 1H), \ 7.48 \ - \ 7.32 \ (m, \ 8H). \ ^{13} C\{1H\} \ NMR \ (100 \ MHz, \ CDCl_3) \\ \delta \ 146.2, \ 138.1, \ 131.2, \ 130.7, \ 130.2, \ 129.5, \ 128, \ 128.7, \ 128.6, \\ 127.7, \ 127.5. \ HRMS \ (ESI) \ m/z \ calcd. \ for \ C_{20}H_{15}N_3Cl^+ \\ 332.0955, \ found \ 332.0960 \ [M+H]^+. \end{array}$

2-(3-bromo-4-fluorophenyl)-4,5-diphenyl-2H-1,2,3triazole (3r). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 98.2 mg (0.25 mmol), 83% yield, m.p. 82–84 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 7.87 (t, *J* = 8.3 Hz, 1H), 7.69 – 7.58 (m, 4H), 7.51 (dd, *J* = 10.3, 2.0 Hz, 1H), 7.47 – 7.42 (m, 1H), 7.42 – 7.34 (m, 6H). ¹⁹**F NMR** (376 MHz, CDCl₃) δ -118.35. ¹³C{1H} NMR (100 MHz, CDCl₃) δ 154.2 (d, *J* = 260.9 Hz), 146.9, 130.4, 129.0, 128.8, 128.6, 128.0 (d, *J* = 4.0 Hz), 127.7 (d, *J* = 9.0 Hz), 125.9, 121.8 (d, *J* = 8.3 Hz), 121.3 (d, *J* = 23.0 Hz). **HRMS** (ESI) m/z calcd. for C₂₀H₁₅N₃FBr⁺ 394.0355, found 394.0361 [M+H]⁺.

2-(naphthalen-1-yl)-4,5-diphenyl-2H-1,2,3-triazole

(3s). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 62.5 mg (0.18 mmol), 60% yield, m.p. 42-44 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.51 – 8.42 (m, 1H), 8.00 (d, *J* = 5.7 Hz, 1H), 7.96 (d, *J* = 6.5 Hz, 2H), 7.73 (dd, *J* = 6.5, 3.1 Hz, 4H), 7.64 – 7.57 (m, 3H), 7.49 – 7.36 (m, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 146.1, 136.9, 135.0, 134.7, 130.9, 130.1, 129.6, 129.3, 129.2, 128.9, 128.8, 128.7, 128.4, 127.6, 127.6, 126.8, 125.2, 124.0, 122.9. HRMS (ESI) m/z calcd. for C₂₄H₁₈N₃+ 348.1501, found 348.1494 [M+H]⁺.

2-([1,1'-biphenyl]-2-yl)-4,5-diphenyl-2H-1,2,3-

triazole (3t). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.4), 100.8 mg (0.27 mmol), 90% yield, m.p. 82–84 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 7.89 – 7.81 (m, 1H), 7.61 – 7.50 (m, 3H), 7.44 (dd, *J* = 6.6, 2.9 Hz, 4H), 7.39 – 7.29 (m, 9H), 7.23 (dd, *J* = 6.6, 2.9 Hz, 2H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 145.5, 139.1, 138.6, 137.9, 131.3, 130.9, 129.3, 128.6, 128.6, 128.5, 128.4, 128.3, 128.2, 127.3, 126.0. HRMS (ESI) m/z calcd. for C₂₆H₂₀N₃⁺ 374.1657, found 374.1660 [M+H]⁺.

methyl 3-(4,5-diphenyl-2H-1,2,3-triazol-2yl)thiophene-2-carboxylate (3u). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 86.7 mg (0.24 mmol), 80% yield, m.p. 111–113 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.64 (dd, *J* = 6.3, 2.8 Hz, 4H), 7.56 (d, *J* = 5.3 Hz, 1H), 7.48 (d, *J* = 5.3 Hz, 1H), 7.44 – 7.29 (m, 6H), 3.85 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 160.9, 146.2, 140.6, 130.6, 129.9, 128.8, 128.7, 128.6, 126.1, 124.4, 52.5. HRMS (ESI) m/z calcd. for C₂₀H₁₆N₃O₂S⁺ 362.0963, found 362.0966 [M+H]⁺.

3-(4,5-diphenyl-2H-1,2,3-triazol-2-yl)quinoline (3v). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.1$), 43.9 mg (0.13 mmol), 42% yield, m.p. 157–159 °C. ¹H NMR (400 MHz, CDCl₃) δ 9.82 (d, *J* = 2.4 Hz, 1H), 8.85 (d, *J* = 2.1 Hz, 1H), 8.19 (d, *J* = 8.4 Hz, 1H), 7.94 (d, *J* = 8.1 Hz, 1H), 7.74 (dd, *J* = 11.3, 4.0 Hz, 1H), 7.69 (dd, *J* = 6.5, 2.9 Hz, 4H), 7.62 (t, *J* = 7.5 Hz, 1H), 7.52 – 7.34 (m, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 147.2, 147.0, 142.7, 133.2, 130.5, 129.7, 129.7, 129.1, 128.9, 128.7, 128.3, 127.9, 127.7, 123.5. HRMS (ESI) m/z calcd. for C₂₃H₁₇N₄⁺ 349.1453, found 349.1459 [M+H]⁺.

4-phenyl-2,5-di-p-tolyl-2H-1,2,3-triazole (4a). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 82.0 mg (0.25 mmol), 84% yield, m.p. 90–92 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.06 (d, *J* = 8.5 Hz, 2H), 7.73 – 7.60 (m, 2H), 7.54 (d, *J* = 8.1 Hz, 2H), 7.41 (ddd, *J* = 7.0, 6.2, 1.9 Hz, 3H), 7.30 (d, *J* = 8.3 Hz, 2H), 7.21 (d, *J* = 7.9 Hz, 2H), 2.42 (s, 3H), 2.40 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 145.9, 145.7, 138.6, 137.8, 137.3, 131.2, 129.9, 129.4, 128.7, 128.6, 128.6, 128.5, 128.1, 118.8, 21.5, 21.2. HRMS (ESI) m/z calcd. for C₂₂H₂₀N₃+ 326.1657, found 326.1650 [M+H]⁺.

4-(4-fluorophenyl)-5-phenyl-2-(p-tolyl)-2H-1,2,3triazole (4b). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 94.9 mg (0.29 mmol), 96% yield, m.p. 93–95 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.05 (d, *J* = 8.5 Hz, 2H), 7.62 (td, *J* = 5.3, 2.2 Hz, 4H), 7.41 (dd, *J* = 5.0, 1.7 Hz, 3H), 7.30 (d, *J* = 8.2 Hz, 2H), 7.16 – 6.97 (m, 2H), 2.42 (s, 3H). ¹⁹**F NMR** (376 MHz, CDCl₃) δ -112.80. ¹³**C{1H} NMR** (100 MHz, CDCl₃) δ 163.1 (d, *J* = 248.2 Hz), 145.7, 144.9, 137.7, 137.5, 130.9, 130.4, 130.4, 130.0, 128.8, 128.6, 127.1 (d, *J* = 3.3 Hz), 118.8, 115.8 (d, *J* = 21.7 Hz), 21.2. **HRMS** (ESI) m/z calcd. for C₂₁H₁₇N₃F⁺ 330.1407, found 330.1406 [M+H]⁺.

4-(4-chlorophenyl)-5-phenyl-2-(p-tolyl)-2H-1,2,3-

triazole (4c). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 93.4 mg (0.27 mmol), 90% yield, m.p. $109-101 \circ$ C. ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, *J* = 8.5 Hz, 2H), 7.63 (dd, *J* = 6.6, 3.0 Hz, 2H), 7.60 (d, *J* = 8.5 Hz, 2H), 7.42 (dd, *J* = 4.9, 1.6 Hz, 3H), 7.37 (d, *J* = 8.5 Hz, 2H), 7.30 (d, *J* = 8.3 Hz, 2H), 2.42 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 145.8, 144.6, 137.6, 137.6, 134.7, 130.8, 129.9, 129.8, 129.5, 129.0, 128.9, 128.8, 128.6, 118.8, 21.2. HRMS (ESI) m/z calcd. for C₂₁H₁₇N₃Cl⁺ 346.1111, found 346.1109 [M+H]⁺.

4-(furan-2-yl)-5-phenyl-2-(p-tolyl)-2H-1,2,3-triazole (4d). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 52.4mg (0.17 mmol), 58% yield, m.p. $58-60 \circ C.$ ¹H NMR (400 MHz, CDCl₃) δ 8.05 (d, J = 8.4 Hz, 2H), 7.81 - 7.65 (m, 2H), 7.54 (s, 1H), 7.51 - 7.40 (m, 3H), 7.29 (d, J = 8.3 Hz, 2H), 6.68 (d, J = 3.2 Hz, 1H), 6.56 - 6.36 (m, 1H), 2.42 (s, 3H). ¹³C**{1H} NMR** (100 MHz, CDCl₃) δ 145.8, 145.7, 143.1, 137.7, 137.6, 130.6, 129.9, 129.0, 128.8, 128.7, 119.0, 111.5, 109.8, 100.1, 21.2. HRMS (ESI) m/z calcd. for $C_{19}H_{16}N_3O^+$ 302.1293, found 302.1298 [M+H]⁺.

2

3

4

5

6

7

8

9

10

11

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

58 59

60

4-(4-bromophenyl)-5-phenyl-2-(p-tolyl)-2H-1,2,3-

triazole (4e). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 99.5 mg (0.26 mmol), 85% yield, m.p. $106-108 \circ C. {}^{1}\text{H}$ **NMR** (400 MHz, CDCl₃) δ 8.04 (d, *J* = 8.5 Hz, 2H), 7.62 (dd, *J* = 6.6, 3.0 Hz, 2H), 7.53 (s, 4H), 7.46 – 7.37 (m, 3H), 7.30 (d, *J* = 8.2 Hz, 2H), 2.42 (s, 3H). ${}^{13}\text{C}$ **1H} NMR** (100 MHz, CDCl₃) δ 145.9, 144.7, 137.7, 131.9, 131.6, 131.6, 130.8, 130.1, 130.0, 128.9, 128.9, 128.6, 122.9, 118.9, 21.2. **HRMS** (ESI) m/z calcd. for C₂₁H₁₇N₃Br⁺ 390.0606, found 390.0608 [M+H]⁺.

12 4-phenyl-2,5-di-p-tolyl-2H-1,2,3-triazole (4f). 13 Following the geneal procedure A, the product was 14 obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 90.8 mg 15 (0.28 mmol). 93% yield, m.p. 90-92 °C. ¹H NMR (400 MHz, 16 CDCl₃) δ 8.06 (d, J = 8.5 Hz, 2H), 7.73 – 7.60 (m, 2H), 7.54 (d, 17 J = 8.1 Hz, 2H), 7.41 (ddd, J = 7.0, 6.2, 1.9 Hz, 3H), 7.30 (d, J = 18 8.3 Hz, 2H), 7.21 (d, J = 7.9 Hz, 2H), 2.42 (s, 3H), 2.40 (s, 3H). 19 ¹³C{1H} NMR (100 MHz, CDCl₃) δ 145.9, 145.7, 138.6, 20 137.8, 137.3, 131.2, 129.9, 129.4, 128.7, 128.6, 128.6, 128.5, 21 128.1, 118.8, 21.5, 21.2. HRMS (ESI) m/z calcd. for C₂₂H₂₀N₃⁺ 22 326.1657, found 326.1650 [M+H]*. Compound 4f was 23 identidical as 4a. 24

4-(4-chlorophenyl)-5-phenyl-2-(p-tolyl)-2H-1,2,3-

triazole (4g). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 89.2 mg (0.26 mmol), 86% yield, m.p. $109-101 \circ C. {}^{1}H$ **NMR** (400 MHz, CDCl₃) δ 8.05 (d, J = 8.5 Hz, 2H), 7.63 (dd, J = 6.6, 3.0 Hz, 2H), 7.60 (d, J = 8.5 Hz, 2H), 7.42 (dd, J = 4.9, 1.6 Hz, 3H), 7.37 (d, J = 8.5 Hz, 2H), 7.30 (d, J = 8.3 Hz, 2H), 2.42 (s, 3H). ${}^{13}C{1H}$ **NMR** (100 MHz, CDCl₃) δ 145.8, 144.6, 137.6, 137.6, 134.7, 130.8, 129.9, 129.8, 129.5, 129.0, 128.9, 128.8, 128.6, 118.8, 21.2. **HRMS** (ESI) m/z calcd. for $C_{21}H_{17}N_3Cl^+$ 346.1111, found 346.1109 [M+H]*. Compound **4g** was identidical as **4c**.

4-methyl-5-phenyl-2-(p-tolyl)-2H-1,2,3-triazole (4h). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 92.2 mg (0.26 mmol), 88% yield, m.p. 68-70 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.00 (d, *J* = 8.5 Hz, 2H), 7.90 – 7.73 (m, 2H), 7.51 (dd, *J* = 10.3, 4.7 Hz, 2H), 7.45 – 7.36 (m, 1H), 7.30 (d, *J* = 8.2 Hz, 2H), 2.61 (s, 3H), 2.43 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 146.2, 142.6, 137.8, 137.0, 131.2, 129.9, 128.9, 128.3, 127.5, 118.5, 21.2, 12.1. HRMS (ESI) m/z calcd. for C₁₆H₁₆N₃⁺ 250.1344, found 250.1345 [M+H]⁺.

4-cyclopropyl-5-(2-fluorophenyl)-2-(p-tolyl)-2H-

50 1,2,3-triazole (4i). Following the geneal procedure A, the 51 product was obtained as a yellow solid after column 52 chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 53.7 mg (0.18 mmol), 61% yield, m.p. 41-43 °C. ¹H 53 **NMR** (400 MHz, CDCl₃) δ 8.00 (d, I = 8.4 Hz, 2H), 7.74 (t, I =54 6.9 Hz, 1H), 7.49 (d, J = 7.7 Hz, 1H), 7.38 – 7.28 (m, 4H), 2.46 55 (s, 3H), 2.12 – 1.85 (m, 1H), 1.18 – 0.96 (m, 4H). ¹⁹F NMR 56 (376 MHz, CDCl₃) δ -113.06.¹³C{1H} NMR (100 MHz, CDCl₃) 57

δ 160.2 (d, *J* = 249.7 Hz), 149.9, 142.1, 137.8, 137.0, 131.6 (d, *J* = 3.1 Hz), 130.5 (d, *J* = 8.0 Hz), 129.8, 124.4 (d, *J* = 3.7 Hz), 119.2 (d, *J* = 14.7 Hz), 118.6, 116.3 (d, *J* = 21.7 Hz), 21.2, 8.6, 6.8. **HRMS** (ESI) m/z calcd. for $C_{18}H_{17}N_3F^+$ 294.1407, found 294.1411 [M+H]⁺.

4-pentyl-5-phenyl-2-(p-tolyl)-2H-1,2,3-triazole (4j). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 48.9 mg (0.16 mmol), 80% yield, m.p. 40-42 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.02 (d, J = 8.4 Hz, 2H), 7.80 (d, J = 7.3 Hz, 2H), 7.51 (t, J = 7.5 Hz, 2H), 7.43 (t, J = 7.4 Hz, 1H), 7.35 – 7.21 (m, 2H), 3.03 – 2.87 (m, 2H), 2.43 (s, 3H), 1.84 (dt, J = 15.3, 7.6 Hz, 2H), 1.48 – 1.34 (m, 4H), 0.95 (t, J = 7.0 Hz, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 147.0, 146.0, 137.9, 136.9, 131.4, 129.8, 128.8, 128.3, 127.7, 118.6, 31.8, 28.7, 26.1, 22.5, 21.1, 14.1. HRMS (ESI) m/z calcd. for C₂₀H₂₄N₃⁺ 306.1970, found 306.1968 [M+H]⁺.

4-phenethyl-5-phenyl-2-(p-tolyl)-2H-1,2,3-triazole (4k). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 84.5 mg (0.25 mmol), 83% yield, m.p. 77-79 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.03 (d, J = 8.5 Hz, 2H), 7.80 - 7.66 (m, 2H), 7.49 (t, J = 7.4 Hz, 2H), 7.46 - 7.38 (m, 1H), 7.38 - 7.18 (m, 7H), 3.35 - 3.23 (m, 2H), 3.21 - 3.10 (m, 2H), 2.44 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 146.2, 146.0, 141.5, 137.9, 137.0, 131.2, 129.9, 128.9, 128.6, 128.4, 127.7, 126.3, 118.7, 35.1, 28.3, 21.2. HRMS (ESI) m/z calcd. for $C_{23}H_{22}N_3^+$ 340.1814, found 340.1814 [M+H]⁺.

4-phenyl-5-(1-phenylethyl)-2-(p-tolyl)-2H-1,2,3-

triazole (41). Following the geneal procedure **A**, the product was conducted at 40 °C with a heating mantle and obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 76.7 mg (0.22 mmol), 72% yield, m.p. 60–62 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.14 (d, *J* = 8.5 Hz, 2H), 7.65 (dd, *J* = 8.0, 1.4 Hz, 2H), 7.52 – 7.41 (m, 5H), 7.41 – 7.32 (m, 4H), 7.29 (d, *J* = 7.9 Hz, 1H), 4.51 (q, *J* = 7.2 Hz, 1H), 2.48 (s, 3H), 1.85 (d, *J* = 7.2 Hz, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 149.4, 146.3, 145.0, 138.0, 137.0, 131.0, 129.8, 128.7, 128.6, 128.4, 128.3, 127.7, 126.5, 118.7, 37.1, 23.3, 21.2. HRMS (ESI) m/z calcd. for $C_{23}H_{22}N_3^+$ 340.1814, found 340.1813 [M+H]⁺.

4-methyl-5-phenyl-2-(p-tolyl)-2H-1,2,3-triazole

(4m). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 98.5 mg (0.28 mmol), 94% yield, m.p. 68–70 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.00 (d, J = 8.5 Hz, 2H), 7.90 – 7.73 (m, 2H), 7.51 (dd, J = 10.3, 4.7 Hz, 2H), 7.45 – 7.36 (m, 1H), 7.30 (d, J = 8.2 Hz, 2H), 2.61 (s, 3H), 2.43 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 146.2, 142.6, 137.8, 137.0, 131.2, 129.9, 128.9, 128.3, 127.5, 118.5, 21.2, 12.1. HRMS (ESI) m/z calcd. for C₁₆H₁₆N₃⁺ 250.1344, found 250.1345 [M+H]⁺. Compound **4m** was identidical as **4h**.

Synthesis of 4,5-diphenyl-2H-1,2,3-triazole (5). A 10 mL Schlenk tube equipped with a stirring bar and capped with a rubber septum was charged with **3f** (0.5 mmol) and

CAN (1.35 mmol). The tube was degassed and backfilled with argon (3 times). CH₃CN (5 mL) and H₂O (0.5 mL) was added into the tube via a syringe. The reaction mixture was cooled down to -10 °C, and was stirred under an argon atmosphere. The reaction was complete in 6 days (monitored by TLC). The resulting mixture was extracted with CH_2Cl_2 (15 mL × 3) and water (10 mL), and the combined organic layers were dried over anhydrous Na₂SO₄ and concentrated in vacuo. The residue was purified by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate = 10:1 and then 5:1) to give 5. The title compound was obtained as a white solid after column chromatography (petroleum ether/ethyl acetate = 6:1, R_f = 0.2), 75.2 mg (0.34 mmol), 68% yield, m.p. 128–130 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (s, 4H), 7.36 (s, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 142.7, 130.2, 128.8, 128.7, 128.4. HRMS (ESI) m/z calcd. for C₁₄H₁₂N_{3⁺} 222.1031, found 222.1031 [M+H]⁺.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

Synthesis of Triazoles 6a and 6b via *N***-Methylations.** A 10 mL Schlenk tube equipped with a stirring bar and capped with a rubber septum was charged with 5 (44.2 mg, 0.2 mmol) and K_2CO_3 (55.2 mg, 0.4 mmol). The tube was degassed and backfilled with argon gas (3 times). DMF (1mL) was added into the tube via a syringe and the reaction mixture was cooled down to 0 °C. Then the addition of CH₃I (56.8 mg, 0.4 mmol) was added. The reaction mixture was stirred at 0 °C for 8 h. Upon completion of the reaction (monitored by TLC), the reaction mixture was purified by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate = 6:1) to give **6a** and **6b**.

2-methyl-4,5-diphenyl-2H-1,2,3-triazole (6a). Obtained as a white solid after column chromatography (petroleum ether/ethyl acetate = 6:1, R_f = 0.5), 23.1 mg (0.01 mmol), 49% yield, m.p. 58–60 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.55 (dd, *J* = 6.4, 2.9 Hz, 4H), 7.42 – 7.29 (m, 6H), 4.27 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 144.7, 131.2, 128.7, 128.4, 128.3, 41.9. HRMS (ESI) m/z calcd. for C₁₅H₁₄N₃⁺ 236.1188, found 236.1188 [M+H]⁺.

1-methyl-4,5-diphenyl-1H-1,2,3-triazole(6b).Obtained as a white solid after column chromatography(petroleum ether/ethyl acetate = 6:1, $R_f = 0.2$), 23.1 mg(0.01 mmol), 49% yield, m.p. 122-124 °C. ¹H NMR (400MHz, CDCl₃) δ 7.62 - 7.54 (m, 2H), 7.55 - 7.45 (m, 3H), 7.41- 7.32 (m, 2H), 7.28 (d, J = 7.2 Hz, 3H), 3.94 (s, 3H). ¹³C{1H}NMR (100 MHz, CDCl₃) δ 144.5, 134.2, 131.1, 13.0, 129.8,129.5, 128.6, 128.0, 127.8, 127.0, 35.4. HRMS (ESI) m/zcalcd. for C₁₅H₁₄N₃+ 236.1188, found 236.1190 [M+H]⁺.

Synthesis of Triazoles 7a and 7b via *N*-Benzylations. A 10 mL Schlenk tube equipped with a stirring bar and capped with a rubber septum was charged with 5 (55.3 mg, 0.25 mmol) and K_2CO_3 (69.1 mg, 0.5 mmol). The tube was degassed and backfilled with argon gas (3 times). Acetone (3mL) was added into the tube via a syringe. Then BnBr (64.1 mg, 0.38 mmol) was added and the resulting reaction mixture was stirred at room temperature for 12 h at 30 °C with a heating mantle. Upon completion of the reaction (monitored by TLC), the solvent was removed by rotary evaporator, the mixture was purified by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate = 6:1) to give **7a** and **7b**.

2-benzyl-4,5-diphenyl-2H-1,2,3-triazole (7a). Obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 6:1, $R_f = 0.5$), 49.8 mg (0.16 mmol), 64% yield, m.p. 79–81 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.60 (dd, J = 6.5, 3.1 Hz, 4H), 7.47 (d, J = 6.9 Hz, 2H), 7.45 – 7.31 (m, 9H), 5.68 (s, 2H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 144.9, 135.4, 131.2, 128.9, 128.6, 128.4, 128.4, 128.2, 58.9. HRMS (ESI) m/z calcd. for C₂₁H₁₈N₃⁺ 312.1501, found 312.1504 [M+H]⁺.

1-benzyl-4,5-diphenyl-1H-1,2,3-triazole (7b). Obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 6:1, $R_f = 0.2$), 24.9 mg (0.08 mmol), 32% yield, m.p. 102-104 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.60 (dd, *J* = 7.8, 1.7 Hz, 2H), 7.51 (d, *J* = 7.3 Hz, 1H), 7.45 (t, *J* = 7.3 Hz, 2H), 7.35 – 7.22 (m, 6H), 7.23 – 7.14 (m, 2H), 7.07 (m, 2H), 5.45 (s, 2H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 144.6, 135.5, 134.0, 131.1, 130.2, 129.8, 129.3, 128.8, 128.5, 128.2, 128.0, 127.8, 127.6, 126.8, 52.2. HRMS (ESI) m/z calcd. for C₂₁H₁₈N₃⁺ 312.1501, found 312.1503 [M+H]⁺.

Synthesis of Triazoles 8a and 8b via *N*-alkylations. A 10 mL Schlenk tube equipped with a stirring bar and capped with a rubber septum was charged with 5 (44.0 mg, 2 mmol) and K_2CO_3 (55.2 mg, 0.4 mmol). The tube was degassed and backfilled with argon gas (3 times). DMF (2mL) was added into the tube via a syringe. Then BrCH₂CO₂Et (66.8 mg, 0.4 mmol) was added and the resulting reaction mixture was stirred at room temperature for 8 h. Upon completion of the reaction (monitored by TLC), the solvent was removed by rotary evaporator, the mixure was purified by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate = 6:1) to give **8a** and **8b**.

ethyl 2-(4,5-diphenyl-2H-1,2,3-triazol-2-yl)acetate (8a). Obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 6:1, R_f = 0.6), 46.0 mg (0.16 mmol), 75% yield, m.p. 101-103 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.56 (d, *J* = 3.3 Hz, 4H), 7.36 (s, 6H), 5.27 (s, 2H), 4.29 (q, *J* = 7.1 Hz, 2H), 1.31 (t, *J* = 7.1 Hz, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 166.9, 145.7, 130.9, 128.7, 128.6, 128.5, 62.3, 55.8, 14.3. HRMS (ESI) m/z calcd. for C₁₈H₁₈N₃O₂⁺ 308.1399, found 308.1400 [M+H]⁺.

ethyl 2-(4,5-diphenyl-1H-1,2,3-triazol-1-yl)acetate (8b). Obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 6:1, R_f = 0.3), 9.2 mg (0.03 mmol), 15% yield, m.p. 42-44 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.58 (dd, *J* = 7.5, 2.2 Hz, 2H), 7.54 – 7.45 (m, 3H), 7.31 – 7.27 (m, 2H), 5.99 (s, 2H), 4.19 (q, *J* = 7.1 Hz, 2H), 1.22 (t, *J* = 7.1 Hz, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 166.6, 144.5, 134.7, 130.9, 130.1, 130.1, 129.6, 128.6, 128.0, 127.6, 127.0, 62.4, 49.4, 14.2. HRMS (ESI) m/z calcd. for C₁₈H₁₈N₃O₂⁺ 308.1399, found 308.1403 [M+H]⁺.

Generation Procedure B: Synthesis of 1,2,3-Traizoles bearing Electron-Deficient *N***-aryl groups (9).** A 10 mL Schlenk tube equipped with a stirring bar and capped with Page 11 of 14

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

58 59

60

a rubber septum was charged with 5 (0.05 mmol), ArX (0.05 mmol) and K_2CO_3 (0.05 mmol). The tube was degassed and backfilled with argon gas (3 times). DMF (0.5 mL) was added into the tube via a syringe. The reaction mixture was stirred for 5 h at 70-120 °C with a heating mantle. Upon completion of the reaction (monitored by TLC), the solvent was removed by rotary evaporator. The residue was purified by flash column chromatography on silica gel (eluting with petroleum ether/ethyl acetate = 10:1) to give **9**.

2-(4-nitrophenyl)-4,5-diphenyl-2H-1,2,3-triazole

(9a). Following the Generation Procedure **B**, the reaction mixture was stirred for 5 h at 120 °C and the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 10:1, $R_f = 0.5$), 16.3 mg (0.05 mmol), 95% yield, m.p. 151–153 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.44 – 8.30 (m, 4H), 7.65 (dd, *J* = 6.5, 2.9 Hz, 4H), 7.51 – 7.33 (m, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 147.9, 146.4, 143.7, 130.1, 129.4, 128.9, 128.6, 125.4, 118.9. HRMS (ESI) m/z calcd. for $C_{20}H_{15}N_4O_2^+$ 343.1195, found 343.1194 [M+H]⁺.

2-(2-nitrophenyl)-4,5-diphenyl-2H-1,2,3-triazole

(9b). Following the Generation Procedure **B**, the reaction mixture was stirred for 5 h at 70 °C and the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 6:1, R_f = 0.6), 16.1 mg (0.05 mmol), 94% yield, m.p. 51–53 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.09 (d, *J* = 8.1 Hz, 1H), 7.85 (dd, *J* = 8.0, 1.1 Hz, 1H), 7.77 – 7.67 (m, 1H), 7.61 (dd, *J* = 6.5, 3.1 Hz, 4H), 7.55 (dd, *J* = 11.3, 4.3 Hz, 1H), 7.46 – 7.33 (m, 6H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 147.5, 132.8, 132.3, 130.2, 129.2, 128.8, 128.7, 128.7, 125.0, 125.0, 99.8. HRMS (ESI) m/z calcd. for $C_{20}H_{15}N_4O_2^+$ 343.1195, found 343.1194 [M+H]⁺.

2-(4,5-diphenyl-2H-1,2,3-triazol-2-yl)benzonitrile

(9c). Following the Generation Procedure **B**, the reaction mixture was stirred for 5 h at 120 °C and the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 6:1, $R_f = 0.4$), 15.3 mg (0.05 mmol), 95% yield, m.p. 99–101 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.19 (d, J = 8.3 Hz, 1H), 7.87 (dd, J = 7.8, 1.3 Hz, 1H), 7.79 – 7.64 (m, 5H), 7.54 – 7.35 (m, 7H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 147.3, 140.5, 135.4, 133.7, 130.2, 129.2, 128.8, 128.7, 127.7, 122.2, 117.2, 104.6. HRMS (ESI) m/z calcd. for C₂₁H₁₅N₄⁺ 323.1297, found 323.1297 [M+H]⁺.

2-(2-fluoro-4-nitrophenyl)-4,5-diphenyl-2H-1,2,3-

45 triazole (9d). Following the Generation Procedure B, the 46 reaction mixture was stirred for 5 h at 90 °C and the product 47 was obtained as a yellow solid after column 48 chromatography (petroleum ether/ethyl acetate = 6:1, R_f = 49 0.6), 15.3 mg (0.04 mmol), 85% yield, m.p. 128-130 °C. ¹H **NMR** (400 MHz, CDCl₃) δ 8.30 (t, *J* = 8.2 Hz, 1H), 8.27 – 8.17 50 (m, 2H), 7.64 (dd, J = 7.1, 2.4 Hz, 4H), 7.41 - 7.26 (m, 6H). ¹⁹F 51 NMR (376 MHz, CDCl₃) δ -115.50. ¹³C{1H} NMR (100 MHz, 52 CDCl₃) δ 153.0 (d, J = 261.9 Hz), 148.1 (d, J = 2.0 Hz), 146.7 53 (d, I = 7.6 Hz), 132.9 (d, I = 8.2 Hz), 129.9, 129.4, 128.9,54 128.7, 124.3, 120.1 (d, J = 4.0 Hz), 114.3 (d, J = 25.2 Hz). 55 HRMS (ESI) m/z calcd. for $C_{20}H_{14}N_4O_2F^+$ 361.1101, found 56 361.1109 [M+H]+. 57

2-(4,5-diphenyl-2H-1,2,3-triazol-2-yl)-5-

nitropyridine (9e). Following the Generation Procedure **B**, the reaction mixture was stirred for 5 h at 80 °C and the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 6:1, R_f = 0.4), 16.5 mg (0.05 mmol), 96% yield, m.p. 170–172 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 9.25 (d, *J* = 2.5 Hz, 1H), 8.67 (dd, *J* = 9.1, 2.6 Hz, 1H), 8.35 (d, *J* = 9.1 Hz, 1H), 7.66 (dd, *J* = 7.6, 1.5 Hz, 4H), 7.51 – 7.33 (m, 6H). ¹³C{1H} **NMR** (100 MHz, CDCl₃) δ 153.4, 149.4, 145.7, 143.0, 134.4, 129.7, 129.6, 128.8, 113.6. **HRMS** (ESI) m/z calcd. for C₁₉H₁₄N₅O₂⁺ 344.1147, found 344.1145 [M+H]⁺.

2-(4,5-diphenyl-2H-1,2,3-triazol-2-yl)-3-

nitropyridine (9f). Following the Generation Procedure **B**, the reaction mixture was stirred for 5 h at 120 °C and the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 6:1, R_f = 0.2), 14.9 mg (0.04 mmol), 87% yield, m.p. 126–128 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 8.82 (dd, *J* = 4.7, 1.5 Hz, 1H), 8.22 (dd, *J* = 8.0, 1.5 Hz, 1H), 7.71 – 7.58 (m, 4H), 7.55 (dd, *J* = 8.0, 4.8 Hz, 1H), 7.7 – 7.32 (m, 6H). ¹³C{1H} **NMR** (100 MHz, CDCl₃) δ 151.5, 148.6, 142.2, 139.5, 134.2, 129.7, 129.4, 128.9, 128.8, 123.5. **HRMS** (ESI) m/z calcd. for C₁₉H₁₄N₅O₂⁺ 344.1147, found 344.1147 [M+H]⁺.

methyl 2-(4,5-diphenyl-2H-1,2,3-triazol-2-yl)-5methylbenzoate (10a). Following the geneal procedure A, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 97.5 mg (0.26 mmol), 88% yield, m.p. 105-107 °C. ¹H NMR (400 MHz, CDCl₃) δ 7.87 (d, *J* = 8.2 Hz, 1H), 7.63 (dd, *J* = 6.5, 3.0 Hz, 4H), 7.56 (s, 1H), 7.47 - 7.32 (m, 7H), 3.78 (s, 3H), 2.45 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 168.2, 146.0, 138.5, 135.7, 132.3, 130.8, 130.3, 128.7, 128.7, 128.6, 128.5, 126.5, 123.5, 52.7, 21.1. HRMS (ESI) m/z calcd. for C₂₃H₂₀N₃O₂⁺ 370.1556, found 370.1563 [M+H]⁺.

methyl 2-(4,5-diphenyl-2H-1,2,3-triazol-2-yl)-5methoxybenzoate (10b). Following the geneal procedure **A**, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 70.5 mg (0.18 mmol), 61% yield, m.p. 43-45 °C. ¹**H NMR** (400 MHz, CDCl₃) δ 7.86 (d, J = 8.9 Hz, 1H), 7.63 (dd, J= 6.4, 2.8 Hz, 4H), 7.47 - 7.34 (m, 6H), 7.31 - 7.26 (m, 1H), 7.13 (dd, J = 8.9, 2.8 Hz, 1H), 3.89 (s, 3H), 3.77 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 167.4, 159.3, 145.8, 131.7, 130.9, 128.7, 128.5, 128.0, 125.6, 117.6, 114.6, 55.9, 52.7. **HRMS** (ESI) m/z calcd. for $C_{23}H_{20}N_3O_3^+$ 386.1505, found 386.1506 [M+H]⁺.

methyl 2-(4,5-diphenyl-2H-1,2,3-triazol-2-yl)-6fluorobenzoate (10c). Following the geneal procedure A, the product was obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, R_f = 0.3), 101.9 mg (0.27 mmol), 91% yield, m.p. 113-115 °C. ¹H NMR (400 MHz, CDCl₃) δ 8.01 (d, *J* = 8.3 Hz, 1H), 7.63 (dd, *J* = 6.6, 2.9 Hz, 4H), 7.52 (td, *J* = 8.3, 6.0 Hz, 1H), 7.45 – 7.32 (m, 6H), 7.14 (t, *J* = 8.5 Hz, 1H), 7.14 (t, *J* = 8.5 Hz, 1H), 3.93 (s, 3H). ¹⁹F NMR (376 MHz, CDCl₃) δ -114.13. ¹³C{1H} NMR (100 MHz, CDCl₃) δ 164.6, 160.0 (d, *J* = 250.0 Hz), 146.6, 137.4 (d, *J* = 6.0 Hz), 131.5 (d, *J* = 9.4 Hz), 130.3, 129.1, 128.7, 128.5, 116.4 (d, J = 3.3 Hz), 115.1 (d, J = 23.0 Hz), 114.7, 114.5, 53.2. **HRMS** (ESI) m/z calcd. for C₂₂H₁₇N₃O₂F⁺ 374.1305, found 374.1308 [M+H]⁺.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

57

58 59

60

Synthesis of 1,1'-Binaphthalene Scaffolds bearing 1,2,3-Triazoles (11a and 11b). An oven-dried 10 mL Schlenk tube equipped with a stirring bar and capped with a rubber septum was charged with 2H-azirine (1f', 0.3 mmol), arene-diazonium salt (0.6 mmol), CuBr (0.06 mmol), and DABCO (0.3 mmol). The tube was evacuated under *vacuo* and then backfilled with argon (for three times). CH₃CN (3.0 mL) was transferred into the tube via a syringe. The resulting mixture was stirred under an argon atmosphere at room temperature for 16 h. The reaction mixture was concentrated *in vacuo*, and the residue was purified by flash chromatography on silica gel (eluting with petroleum ether / ethyl acetate) to give the desired product 11a and 11b.

2-([1,1'-binaphthalen]-2-yl)-4-phenyl-5-(p-tolyl)-

2H-1,2,3-triazole (11a). Obtained as a yellow solid after column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 38.0 mg (0.01 mmol), 26% yield, m.p. 56-55 °C. $[\alpha]_D^{20} = -167.8 (c 1.0, CH_2Cl_2)$. ¹H NMR (400 MHz, CDCl₃) δ 8.15 (d, J = 8.8 Hz, 2H), 8.01 (d, J = 8.2 Hz, 1H), 7.95 (d, J = 7.9 Hz, 2H), 7.63 – 7.32 (m, 7H), 7.29 (d, J = 8.2 Hz, 1H), 7.25 – 7.17 (m, 3H), 7.17 – 7.10 (m, 2H), 7.09 – 6.96 (m, 4H), 2.32 (s, 3H). ¹³C{1H} NMR (100 MHz, CDCl₃) δ 145.1, 144.9, 138.2, 136.9, 134.9, 133.8, 133.7, 133.5, 133.1, 132.0, 130.9, 129.3, 129.1, 128.8, 128.4, 128.3, 128.2, 128.1, 128.1, 127.8, 127.6, 127.1, 126.8, 126.9, 126.3, 125.8, 125.4, 122.6, 21.4. HRMS (ESI) m/z calcd. for $C_{35}H_{26}N_3^+$ 488.2127, found 488.2126 [M+H]⁺.

2,2'-bis(4-phenyl-5-(p-tolyl)-2H-1,2,3-triazol-2-yl)-1,1'-binaphthalene (11b). Obtained as a yellow solid after

column chromatography (petroleum ether/ethyl acetate = 30:1, $R_f = 0.3$), 51.9 mg (0.01 mmol), 24% yield, m.p. $110-112 \,^{\circ}C. [\alpha]_D{}^{20} = +123 (c 1.0, CH_2Cl_2). {}^{1}H NMR (400 MHz, CDCl_3) \delta 8.23 (d, <math>J = 8.9 Hz, 2H$), 8.11 (d, J = 8.9 Hz, 2H), 8.00 (d, <math>J = 8.1 Hz, 2H), 7.55 - 7.41 (m, 4H), 7.36 - 7.29 (m, 2H), 7.24 - 7.19 (m, 2H), 7.17 (d, J = 7.9 Hz, 3H), 7.13 (d, J = 7.7 Hz, 5H), 7.02 (d, J = 8.1 Hz, 4H), $6.96 (d, J = 8.1 Hz, 4H), 2.30 (s, 6H). {}^{13}C{1H} NMR (100 MHz, CDCl_3) \delta 145.2, 145.0, 138.0, 136.9, 134.4, 132.8, 131.1, 129.3, 129.0, 128.3, 128.2, 128.2, 128.1, 128.0, 128.0, 127.4, 127.3, 126.5, 121.9, 21.4. HRMS (ESI) m/z calcd. for <math>C_{50}H_{37}N_6{}^+$ 721.3080, found 721.3081 [M+H]⁺.

45 Radical trap experiment. An oven-dried 10 mL Schlenk 46 tube equipped with a stirring bar and capped with a rubber 47 septum was charged with 2H-azirine (1a, 0.3 mmol), 48 aryldiazonium salt (2a, 0.6 mmol), CuBr (0.06 mmol), 49 DABCO (0.3 mmol), and TEMPO (0.6 mmol). The tube was evacuated under vacuo and then backfilled with argon (for 50 three times). CH₃CN (3.0 mL) was transferred into the tube 51 via a syringe. The resulting mixture was stirred under an 52 argon atmosphere at room temperature for 16 h and then 53 subjected to HRMS analysis. The mass spectra presented a 54 peak at m/z 351.2430, which likely corresponded to the 55 TEMPO-trapped product 12. 56

ASSOCIATED CONTENT

Supporting Information

The Supporting Information is available free of charge on the ACS Publications website.

Experimental details and spectral data of all new compounds (PDF).

AUTHOR INFORMATION

Corresponding Author

- * E-mail: zhiwei.zhang@tju.edu.cn (C.W.C.)
- * E-mail: majun_an68@tju.edu.cn. (J.-A.M.)

ORCID

Fa-Guang Zhang: 0000-0002-0251-0456

Chi Wai Cheung: 0000-0003-4415-0767

Jun-An Ma: 0000-0002-3902-6799

Notes

The authors declare no competing financial interest.

ACKNOWLEDGMENT

We thank the National Key Research and Development Program of China (No. 2019YFA0905100), the National Natural Science Foundation of China (No. 21532008, 21772142, 21901181, and 21971186) and Tianjin University (start-up grants) for financial support.

REFERENCES

(1) For selected reviews on the synthesis and applications of N¹-substituted 1,2,3-triazoles, see: (a) Kolb, H. C.; Sharpless, K. B. The growing impact of click chemistry on drug discovery. Drug. Discov. Today. 2003, 8, 1128-1137. (b) Moses, J. E.; Moorhouse, A. D. The growing applications of click chemistry. Chem. Soc. Rev. 2007, 36, 1249-1262. (c) Wu, P.; Fokin, V. V. Catalytic Azide-Alkyne Cycloaddition: Reactivity and Applications. Aldrichim. Acta. 2007, 40, 7-17. (d) Nandivada, H.; Jiang, X. W.; Lahann, J. Click Chemistry: Versatility and Control in the Hands of Materials Scientists. Adv. Mater. 2007, 19, 2197-2208. (e) Moses, J. E.; Moorhouse, A. D. The growing applications of click chemistry. Chem. Soc. Rev. 2007, 36, 1249-1262. (f) Meldal, M.; Tornøe, C. W. Cu-Catalyzed Azide-Alkyne Cycloaddition. Chem. Rev. 2008, 108, 2952-3015. (g) Tron, G. C.; Pirali, T.; Billington, R. A.; Canonico, P. L.; Sorba, G.; Genazzani A. A. Click Chemistry Reactions in Medicinal Chemistry: Applications of the 1,3-dipolar Cycloaddition Between Azides and Alkynes. Med. Res. Rev. 2008, 28, 278-308. (h) Agalave, S. G.; Maujan, S. R.; Pore, V. S. Click Chemistry: 1.2.3-Triazoles as Pharmacophores. Chem. Asian I. 2011. 6. 2696-2718. (i) Thirumurugan, P.; Matosiuk, D.; Jozwiak, K. Click Chemistry for Drug Development and Diverse Chemical-Biology Applications. Chem. Rev. 2013, 113, 4905-4979.

(2) For examples of the applications of N^2 -aryl-1,2,3-triazoles, see: (a) Cox, C. D.; Breslin, M. J.; Whitman, D. B.; Schreier, J. D.; McGaughey, G. B.; Bogusky, M. J.; Roecker, A. J.; Mercer, S. P.; Bednar, R. A.; Lemaire, W.; Bruno, J. G.; Reiss, D. R.; Harrell, C. M.; Murphy, K. L.; Garson, S. L.; Doran, S. M.; Prueksaritanont, T.; Anderson, W. B.; Tang, C. Y.; Roller, S.; Cabalu, T. D.; Cui, D. H.; Hartman, G. D.; Young, S. D.; Koblan, K.

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

51

52

53

54

55

56

57

58 59

60

S.; Winrow, C. J.; Renger, J. J.; Coleman, P. J. Discovery of the Dual Orexin Receptor Antagonist [(7R)-4-(5-Chloro-1,3-benzoxazol-2-yl)-7-methyl-1,4-diazepan-1-yl][5-methyl-2-(2H-1,2,3-

2 triazol-2-yl)phenyl]methanone (MK-4305) for the Treatment 3 of Insomnia. J. Med. Chem. 2010, 53, 5320-5332. (b) Baxter, C. 4 A.; Cleator, E.; Brands, K. M. J.; Edwards, J. S.; Reamer, R. A.; 5 Sheen, F. J.; Stewart, G. W.; Strotman, N. A.; Wallace, D. J. The 6 First Large-Scale Synthesis of MK-4305: A Dual Orexin 7 Receptor Antagonist for the Treatment of Sleep Disorder. Org. 8 Process. Res. Dev. 2011, 15, 367-375. (c) Watanabe, T.; 9 Umezawa, Y. J.; Takahashi, Y.; Akamatsu, Y. Novel pyrrole- and 1,2,3-triazole-based 2,3-oxidosqualene cyclase inhibitors. 10 Bioorg. Med. Chem. Lett. 2011, 20, 5807–5810. (d) Roecker, A. 11 J.; Mercer, S. P.; Harrell, C. M.; Garson, S. L.; Fox, S. V.; Gotter, A. 12 L.; Prueksaritanont, T.; Cabalu, T. D.; Cui, D. H.; Lemaire, W.; 13 Winrow, C. J.; Renger, J. J.; Coleman, P. J. Discovery of dual 14 orexin receptor antagonists with rat sleep efficacy enabled by 15 expansion of the acetonitrile-assisted/diphosgene-mediated 16 2,4-dichloropyrimidine synthesis. Bioorg. Med. Chem. Lett. 2014, 24, 2079-2085. (e) Raheem, I. T.; Breslin, M. J.; Bruno, J.; 17 Cabalu, T. D.; Cooke, A.; Cox, C. D.; Cui D. H.; Garson, S.; Gotter, 18 A. L.; Fox, S. V.; Harrell, C. M.; Kuduk, S. D.; Lemaire, W.; 19 Prueksaritanont, T.; Renger, J. J.; Stump, C.; Tannenbaum, P. L.; 20 Williams, P. D.; Winrow, C. J.; Coleman, P. J. Discovery of 21 piperidine ethers as selective orexin receptor antagonists 22 (SORAs) inspired by filorexant. Bioorg. Med. Chem. Lett. 2015, 23 25, 444-450.

> (3) For examples, see: (a) Hopkins, C. R. Molecule Spotlight on Suvorexant. *ACS. Chem. Neurosci.* **2012**, *3*, 647–648. (b) Sun, H.; Kennedy, W. P.; Wilbraham, D.; Lewis, N.; Calder, N.; Li, X.; Ma, J.; Yee, K. L.; Ermlich, S.; Mangin, E.; Lines, C.; Rosen, L.; Chodakewitz, J.; Murphy, G. M. Effects of Suvorexant, an Orexin Receptor Antagonist, on Sleep Parameters as Measured by Polysomnography in Healthy Men. *Sleep* **2013**, *36*, 259–267. (c) Bennett, T.; Bray, D.; Neville, M. W. Suvorexant, a Dual Orexin Receptor Antagonist for the Management of Insomnia. *P.T.* **2014**, *39*, 264–266.

(4) For examples, see: Hoyer, D.; Allen, A.; Jacobson, L. H. Hypnotics with novel modes of action. *Br. J. Clin. Pharmacol.* **2020**, *86*, 244–249.

(5) For examples, see: (a) Gentile, T. A.; Simmons, S. J.; Barker, D. J.; Shaw, J. K.; España, R. A.; Muschamp, J. W. Suvorexant, an orexin/hypocretin receptor antagonist, attenuates motivational and hedonic properties of cocaine. *Addict. Biol.* 2017, *23*, 247–255. (b) Peter, D. B.; Drevets, W. C.; Rofael, H.; Ark, V. P.; Kent, J. M.; Kezic, I.; Parapatics, S.; Dorffner, G.; Gerven, J. V.; Beneš, H.; Keicher, C.; Jahn, H.; Seiden, D. J.; Luthringer, R. A randomized Phase 2 study to evaluate the orexin-2 receptor antagonist seltorexant in individuals with insomnia without psychiatric comorbidity. *J. Psychopharmacol.* 2018, *32*, 668–677.

(6) For examples, see: (a) Liu, Y. X.; Yan, W. M.; Chen, Y. F.; Petersen, J. L.; Shi, X. D. Efficient Synthesis of *N*-2-Aryl-1,2,3-Triazole Fluorophores via Post-Triazole Arylation. *Org. Lett.* **2008**, *10*, 5389–5392. (b) Wang, X. J.; Zhang, L.; Krishnamurthy, D.; Senanayake, C. H.; Wipf, P. General Solution to the Synthesis of *N*-2-Substituted 1,2,3-Triazoles. *Org. Lett.* **2010**, *12*, 4632– 4635. (c) Satoshi, U.; Su, M.; Buchwald, S. L. Highly *N*²-Selective Palladium-Catalyzed Arylation of 1,2,3-Triazoles. *Angew. Chem. Int. Ed.* **2011**, *50*, 8944–8947. (d) Zhang, Y. Q.; Li, X. L.; Li, J. H.; Chen, J. Y, Meng, X.; Zhao, M. M.; Chen, B. H. CuO-Promoted Construction of *N*-2-Aryl-Substituted-1,2,3-Triazoles via Azide-Chalcone Oxidative Cycloaddition and Post-Triazole Arylation. *Org. Lett.* **2012**, *14*, 26–29. (e) Lopes, A. B.; Wagner, P.; Souza, R. O. M. A.; Germain, N. L.; Uziel, J.; Bourguignon, J. J.; Schmitt, M.; Miranda, L. S. Functionalization of *2H*-1,2,3-Triazole C-Nucleoside Template via *N*² Selective Arylation. *J. Org. Chem.* **2016**, *81*, 4540–4549. (f) Alexandra, B. L.; Patrick, W.; Arthur, E. K.; Frédéric, B.; Bourguignon, J. J; Martine, S.; Leandro, S. M. M. Development of a L-Tryptophan-Based Ligand for Regioselective Copper Catalyzed *N*²-Arylation of 1,2,3-Triazoles. *ChemistrySelect.* **2017**, *2*, 6544–6548.

(7) For examples, see: (a) Hann, R. M.; Hudson, C. S. The action of copper sulfate on phenylosazones of the sugars. Phenyl-D-glucosotriazole. J. Am. Chem. Soc. 1944, 66, 735-738. (b) Riebsomer, J. L.; Sumrell, G. 2-Phenyl-2,1,3-Triazole-4-Carboxaldehyde and Derivatives. J. Org. Chem. 1948, 13, 807-814. (c) El Sekily, M.; Mancy, S.; El Kholy, I.; El Ashry, E. S. H.; El Khadem, H. S.; Swartz, D. L. Reactions of the 3-oxime 2phenylhydrazone and mixed bishydrazones of dehydro-Lascorbic acid: Conversion into substituted triazoles and pyrazolinediones. Carbohydr. Res. 1977, 59, 141-149. (d) Guru, M. M.; Punniyamurthy, T. Copper(II)-Catalyzed Aerobic Oxidative Synthesis of Substituted 1,2,3- and 1,2,4-Triazoles from Bisarylhydrazones via C-H Functionalization/C-C/N-N/C-N Bonds Formation. J. Org. Chem. 2012, 77, 5063-5073. (e) Xu, B.; Hu, Y. Another Way to the Synthesis of 1, 2, 3-Triazoles. J. Heterocycl. Chem. 2013, 50, 1217–1222. (f) Wu, L. Y.; Guo, S.; Wang, X. H.; Guo, Z. F.; Yao, G. G.; Lin, Q.; Wu, M. S. Tandem synthesis of 2-aryl-1,2,3-triazoles from α -arylhydrazonoketones with NH₄OAc via coppercatalyzed aerobic oxidation. Tetrahedron. Lett. 2015, 56, 2145-2148. (g) Shastin, A. V.; Tsyrenova, B. D.; Sergeev, P. G.; Roznyatovsky, V. A.; Smolyar I. V.; Khrustalev, V. N.; Nenajdenko, V. G. Synthesis of a New Family of 1,1-Diazidoethenes: One-Pot Construction of 4-Azido-1,2,3triazoles via Nitrene Cyclization. Org. Lett. 2018, 20, 7803-7806.

(8) For synthesis of N^2 -aryl 1,2,3-triazoles via annulation of aryldiazonium salts, see: (a) Liu, Z. H.; Ji, H. M.; Gao, W.; Zhu, G. Y.; Tong, L. L.; Lei, F. C.; Tang, B. Copper(I)-mediated carboamination of vinyl azides by aryldiazonium salts: synthesis of N²-substituted 1,2,3-triazoles. Chem. Commun. 2017, 53, 6259-6262. (b) Zhu, C. L.; Zeng, H.; Chen, F. L.; Liu, C.; Zhu, R.; Wu, W. Q.; Jiang, H. F. Copper-catalyzed coupling of oxime acetates and arvldiazonium salts: an azide-free strategy toward N-2-aryl-1,2,3-triazoles. Org. Chem. Front. 2018, 5, 571-576. (c) Zhu, C. L.; Zeng, H.; Chen, F. L.; Liu, C.; Jiang, H. F. Copper-Catalyzed Cyclization of Aryl Amines and Aryldiazonium salts under Air: Access to N-2-Aryl-Naphthotriazoles. Adv. Synth. Catal. 2019, 361, 5149-5159. (d) Wu, P.; He, Y.; Wang, H.; Zhou, Y.-G.; Yu, Z. Copper(II)-Catalyzed C-H Nitrogenation/Annulation Cascade of Ketene N, S-Acetals with Aryldiazonium Salts: A Direct Access to N²-Substituted Triazole and Triazine Derivatives. Org. Lett. 2020, 22, 310-315. (e) Liu, H.-N.; Cao, H.-Q.; Cheung, C. W.; Ma, J.-A. Cu-Mediated Expeditious Annulation of Alkyl 3-Aminoacrylates with Aryldiazonium Salts: Access to Alkyl N²-Aryl 1,2,3-Triazolecarboxylates for Druglike Molecular Synthesis. Org. Lett. 2020, 22, 1396-1401.

(9) For recent examples of synthesis of other nitrogen heterocycles based on aryldiazonium salts, see: (a) Liu, J.-Q.; Shen, X. Y.; Wang, Y. H.; Wang, X.-S.; Bi, X. H. [3 + 2] Cycloaddition of Isocyanides with Aryl Diazonium Salts: Catalyst-Dependent Regioselective Synthesis of 1,3- and 1,5-Disubstituted 1,2,4-

Triazoles. Org. Lett. 2018, 20, 6930-6933. (b) Chuprun, Sergey.; Dar'in, D.; Kantin, G.; Krasavin, M. [3+2]-Cycloaddition of α-Diazocarbonyl Compounds with Arenediazonium Salts Catalyzed by Silver Nitrate Delivers 2,5-Disubstituted Tetrazoles. Synthesis 2019, 51, 3998-4005. (c) Wang, M.; Tang, B.-C.; Xiang, J.-C.; Chen, X.-L.; Ma, J.-T.; Wu, Y.-D.; Wu, A.-X. Aryldiazonium Salts Serve as a Dual Synthon: Construction of Fully Substituted Pyrazoles via Rongalite-Mediated Three-Component Radical Annulation Reaction. Org. Lett. 2019, 21, 8934-8937. (d) Yu, X.-Y.; Xiao, W.-J.; Chen, J.-R. Synthesis of Trisubstituted 1,2,4-Triazoles from Aryldiazonium Azlactones and Salts bv Cvcloaddition/Decarboxvlation Cascade, Eur. I. Org. Chem. 2019. 6994-6998. (e) Liu, J.; Xu, E.; Jiang, J.; Huang, Z.; Zheng, L.; Liu, Z.-Q. Copper-mediated tandem ring-opening/cyclization reactions of cyclopropanols with aryldiazonium salts: synthesis of Narylpyrazoles. Chem. Commun. 2020, 56, 2202-2205.

1

2

3

4

5

6

7

8

9

10

11

12

13

14

15

16

17

18

19

20

21

22

23

24

25

26

27

28

29

30

31

32

33

34

35

36

37

38

39

40

41

42

43

44

45

46

47

48

49

50

60

(10) For recent examples of synthesis of nitrogen heterocycles based on azirines, see: (a) Li, T. F.; Xu, F.; Li, X. C.; Wang, C. X.; Wan, B. S. Ruthenium-Catalyzed C-C Bond Cleavage of 2H-Azirines: A Formal [3+2+2] Cycloaddition to Fused Azepine Skeletons. Angew. Chem. Int. Ed. 2016, 55, 2861-2865. (b) Ding, H. L.; Wang, Z. B.; Bai, S. L.; Lu, P.; Wang, Y. G. Rh-Catalyzed Conversion of 3-Diazoindolin-2-imines to 5H-Pyrazino[2,3-b]indoles with Photoluminescent Properties. Org. Lett. 2017, 19, 6514-6517. (c) Shi, S. J.; Xu, K.; Jiang, C.; Ding, Z. H. ZnCl₂-Catalyzed [3 + 2] Cycloaddition of Benzimidates and 2H-Azirines for the Synthesis of Imidazoles. J. Org. Chem. 2018, 83, 14791-14796. (d) Zhao, M.-N.; Ren, Z.-H.; Yang, D.-S.; Guan, Z.-H. Iron-Catalyzed Radical Cycloaddition of 2H-Azirines and Enamides for the Synthesis of Pyrroles. Org. Lett. 2018, 20, 1287-1290. (e) Huang, Y.-J.; Qiao, B.; Zhang, F.-G.; Ma, J.-A. Facile construction of trifluoromethyl-azirines via one-pot metal-free Neber reaction. Tetrahedron 2018, 74, 3791-3796. (f) Cai, B.-G.; Chen, Z.-L.; Xu, G.-Y.; Xuan, J.; Xiao, W.-J. [3 + 2]-Cycloaddition of 2H-Azirines with Nitrosoarenes: Visible-Light-Promoted Synthesis of 2,5-Dihydro-1,2,4-oxadiazoles. Org. Lett. 2019, 21, 4234-4238. (g) Wu, Y.F.; Tian, B.; Witzel, S.; Jin, H. M.; Tian, X. H.; Rudolph, M.; Rominger, F.; Hashmi. A. S. K. AuBr₃-Catalyzed Chemoselective Annulation of Isocyanates with 2H-Azirine. Chem. Eur. J. 2019, 25, 4093-4099.

(11) Our groups have been interested in utilizing aryldiazonium salt for heterocycle synthesis, see: (a) Chen, Z.; Fan, S.-Q.; Zheng, Y.; Ma, J.-A. Silver-catalyzed regioselective [3 + 2] cycloaddition of arene-diazonium salts with 2,2,2-trifluorodiazoethane (CF₃CHN₂): a facile access to 2-aryl-5-trifluoromethyltetrazoles. Chem. Commun. 2015, 51, 16545-16548. (b) Peng, X.; Xiao, M.-Y.; Zeng, J.-L.; Zhang, F.-G.; Ma, J.-A. Construction of Difluoromethylated Tetrazoles via Silver-Catalyzed Regioselective [3 + 2] Cycloadditions of Aryl Diazonium Salts. Org. Lett. 2019, 21, 4808-4811. (c) Zhai, S.-J.; Peng, X.; Zhang, F.-G.; Ma, J.-A. Catalytic Direct Regioselective Synthesis of Phosphonylated Tetrazoles from Aryl Diazonium Salts and Seyferth-Gilbert Reagent. Org. Lett. 2019, 21, 9884-9888. (d) Xiao, M.-Y.; Chen, Z.; Zhang, F. G.; Ma. J.- A. Regioselective synthesis of carboxylic and fluoromethyl tetrazoles enabled by silver-catalyzed cycloaddition of diazoacetates and aryl diazonium salts. Tetrahedron 2020, 76, 131063. (e) For most recent related review, see: Zhang, F.-G.; Chen, Z.; Cheung, C. W.; Ma, J.-A. Aryl Diazonium Salt-Triggered Cyclization and Cycloaddition Reactions: Past, Present, and Future. Chin. J. Chem. 2020, 38, 1132-1152.

(12) Butler, R. N.; Hanniffy, J. M.; Stephens, J. C.; Burke, L. A. A Ceric Ammonium Nitrate *N*-Dearylation of *N*-*p*-Anisylazoles Applied to Pyrazole, Triazole, Tetrazole, and Pentazole Rings: Release of Parent Azoles. Generation of Unstable Pentazole, HN_5/N_5 , in Solution. *J. Org. Chem.* **2008**, *73*, 1354–1364.

(13) (a) Panda, S.; Maity, P.; Manna, D. Transition Metal, Azide, and Oxidant-Free Homo- and Heterocoupling of Ambiphilic Tosylhydrazones to the Regioselective Triazoles and Pyrazoles. *Org. Lett.* **2017**, *19*, 1534-1537. (b) Lai, Qi.; Liu, Q.; He, Y.; Zhao, K.; Wei, C.Y.; Wojtas, L.; Shi, X. D.; Song, Z. G. Triazole-Imidazole (TA-IM) as Ultrafast Fluorescent Probes for Selective Ag⁺ Detection. *Org. Biomol. Chem.* **2018**, *16*, 7801–7805.

(14) Wang, X. J.; Zhang, L.; Lee, H.; Haddad, N.; Krishnamurthy, D.; Senanayake, C. H. Highly Regioselective *N*-2 Arylation of 4,5-Dibromo-1,2,3-triazole: Efficient Synthesis of 2-Aryltriazoles. *Org. Lett.* **2009**, *11*, 5026–5028.

(15) For other reports on synthesis of N^2 -H free 1,2,3-triazoles, see: (a) Tsai, C.-W., Yang, S.-C.; Liu, Y.-M.; Wu, M.-J. Microwaveassisted cycloadditions of 2-alkynylbenzonitriles with sodium azide: selective synthesis of tetrazolo[5,1a]pyridines and 4,5disubstituted-2H-1,2,3-triazoles. Tetrahedron 2009, 65, 8367-8372. (b) Berger, O.; Kaniti, A.; Tran van Ba, C.; Vial, H.; Ward., S. A.; Biagini. G. A.; Bray, P. G.; O'Neill, P. M. Synthesis and Antimalarial Activities of a Diverse Set of Triazole-Containing Furamidine Analogues. ChemMedChem 2011, 6, 2094-2018. (c) Hu, L.; Mick-Lichtenfeld, C.; Wang, T.; He, G.; Gao, M.; Zhao, J. Reaction between Azidyl Radicals and Alkynes: A Straightforward Approach to NH-1,2,3-Triazoles. Chem. Eur. J. 2016, 22, 911-915. (d) Bjerknes, M.; Cheng, H.; McNitt, C. D; Popik, V. V. Facile Quenching and Spatial Patterning of Cylooctynes via Strain-Promoted Alkyne-Azide Cycloaddition of Inorganic Azides. Bioconjugate Chem. 2017, 28, 1560-1565.

(16) (a) Sang, R.; Zheng, Y.; Zhang, H. L.; Wu, X. H.; Wang, Q. T.; Hai, L.; Wu, Y. Palladium-catalyzed direct C-H ethoxycarbonylation of 2-aryl-1,2,3-triazoles and efficient synthesis of suvorexant. *Org. Chem. Front.* **2018**, *5*, 648–652. (b) Zhang, H. L.; Jing, L.; Zheng, Y.; Sang, R.; Zhao, Y.; Wang, Q. T.; Wu, Y. Rhodium-Catalyzed ortho-Cyanation of 2-Aryl-1,2,3-triazole: An Alternative Approach to Suvorexant. *Eur. J. Org. Chem.* **2018**, 723–729.

(17) Cai, R L.; Yan, W. M L.; Bologna, M. G L.; Silva, K. D.; Ma, Z.; Finklea, H. O.; Petersen, J. L.; Li, M. Y.; Shi, X. D. Synthesis and characterization of *N*-2-aryl-1,2,3-triazole based iridium complexes as photocatalysts with tunable photoredox potential. *Org. Chem. Front.* **2015**, *2*, 141–144.

(18) Xuan, J.; Xia, X. D.; Zeng, T. T.; Feng, Z. J.; Chen, J. R.; Lu, L. Q.; Xiao, W. J. Visible-light-induced Formal [3+2] Cycloaddition for Pyrrole Synthesis Under Metal-Free Conditions. *Angew. Chem. Int. Ed.* **2014**, *53*, 5653–5656.

(19) Wang, Y.; Lei X.; Tang, Y. Rh(ii)-catalyzed cycloadditions of 1-tosyl 1,2,3-triazoles with 2*H*-azirines: switchable reactivity of Rh-azavinylcarbene as [2C]- or aza-[3C]-synthon. *Chem. Commun.* **2015**, *51*, 4507–4510.